New drug Kisunla will be 20% more than rival as drugmaker claims it requires fewer treatments
Alcohol, food, tobacco and fossil fuel sectors oppose efforts to target conditions linked to 2.7mn deaths a year, warns WHO
People with cystic fibrosis, epilepsy and diabetes among those struggling with medicine shortages
As the health benefits of anti-obesity medicines widen, pharma companies need to rethink what they charge
For stretched public health budgets, high-tech treatments are hard to afford but some pre-emptive measures can prove good value
US pharma group follows Eli Lilly with website for patients to obtain medication online
US state to buy naloxone nasal spray from generics maker and distribute medication under its own brand
With revenues having more than doubled since 2019, to $10bn, US pharma group targets painkillers
Success of biosimilars in lowering prices will depend on decisions from powerful pharmacy benefit managers
Lenmeldy gene therapy treats MLD, a condition that attacks the central nervous system of young children
Chief executive says customers very willing to pay for Wegovy from their own pockets
US reforms will put Big Pharma under pressure but innovative companies will retain their pricing power
Danish drugmaker reports better than expected earnings for 2023
State will be first to capitalise on rules designed to cut high costs Americans pay for drugs
The Danish company’s drugs for obesity could have a profound impact on healthcare, society and our relationship with food
Danish pharma group in talks with healthcare providers about innovative models to boost Wegovy take-up
A new crop of weight-loss drugs is disrupting markets as well as transforming waistlines
Preliminary probe looks into financial communications around 2017 launch of group’s blockbuster drug Dupixent
Sector has been critical of government after sharp rise in clawback tax
It follows surge in popularity of Ozempic, which is often used for weight loss
Report shows 300% increase in demand for GLP-1 weight loss and diabetes drugs
New rules are designed to make medicines cheaper for American seniors. But companies warn innovation will suffer
Medicare’s negotiations on the cost of medicines could affect how drug research is funded globally
Efforts to rein in soaring health costs have already hit corporate shares but the sell-off looks premature
Expensive medicines made by Pfizer, J&J and Merck selected for talks in biggest shake-up in decades
International Edition